WebFeb 3, 2024 · Results: Median age and prostate-specific antigen level were 73 years and 266.2 ng/ml, respectively. Median OS was 55.5 months in patients who met the CHAARTED high criteria (vs 33.1 months in... WebFor metastatic HSPC, ADT plus docetaxel or ARPI has become a standard treatment, in which the survival benefit of upfront treatment is comparable between the two, especially in high‐volume disease. 41 , 42 Therefore, it is expected that genetic predictive models could be clinically useful to choose the treatment to best fit the individual ...
Impact of pretreatment anemia on upfront abiraterone acetate …
WebAs such, regardless of health care system, due to the broader inclusion criteria of STAMPEDE, applying the more restrictive CHAARTED-HV and LATITUDE criteria would result in around 30% or 50% fewer men being offered docetaxel or abiraterone secondary to ADT, respectively. WebJul 2, 2024 · We then compared the prognosis between CHAARTED criteria with a high volume and that with a low volume. CHAARTED high-volume disease was defined as … coffin walk
Prognostic impact of bone metastatic volume beyond vertebrae
WebFor example, the CHAARTED trial defined high volume disease as the presence of visceral metastases and/or ≥4 bone lesions with ≥1 lesion beyond the vertebral bodies and pelvis. This study revealed the survival benefit of the upfront use of docetaxel only existed in mPC patients with high volume disease but not in those with low volume ... WebCHAARTED criteria with a high volume and that with a low volume. CHAARTED high-volume disease was defined as the presence of visceral metastasis or ≥4 bone lesions … WebApr 11, 2024 · Forest plots of the association between systemic therapy and overall survival for patients with (A) low-volume (n = 3392) and (B) high-volume (n = 6054) metastatic hormone-sensitive prostate cancer according to the CHAARTED criteria, with pooled ARAT + ADT as the reference. (C) Network graph illustrating the connectivity of the treatment … coffin v. united states